Press Releases

BOSTON, March 25, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a biopharmaceutical company committed to defeating cancer using RNA therapeutics, today announced that an interview with Co-Founder, President and CEO, Michael Dudley, will air on The RedChip Money Report® on

BOSTON, March 23, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams from, Massachusetts General Hospital, Michigan State University and Northeastern University, published

BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced that it has filed an International PCT Application (PCT/US21/65580) entitled TEMPLATE DIRECTED IMMUNOMODULATION FOR

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the 2022 BIO CEO & Investor Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific